REMEDIUM BIO INC
Dose-adjustable gene therapy platform enabling post-treatment dose regulation of genetic therapeutics
- Sector
- Biotech
- Headquarters
- Needham, MA
- Founded
- 2020
- Latest Form D
- $1.5M, May 2026
- Total capital
- $3.1M
- Federal grants
- $275K
- 1 award · 2023
- Rank in peer group#144 of 392
- Private capital raised
- $2.9M
- 2 Form D · last May 2026
- 5 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 14 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$1.5M
- Federal grantNSF · Phase I · SBIR Phase I: Development of an Adjustable Gene Therapy Platform Technology$275K
- Private capital raisedForm D · SEC · 1st filing$1.4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grants#144 · top 37%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alexei GoraltchoukExecutive Officer, DirectorNamed in SEC Form D filings
- Frank LuppinoExecutive Officer, DirectorNamed in SEC Form D filings
- Harry RobbDirectorNamed in SEC Form D filings
- Luppino FrancescoExecutive Officer, DirectorNamed in SEC Form D filings
- Richard HagueDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 14- PendingAdjustable Gene TherapyUSPTOApplication 19357344
- PendingTreatment For OsteoarthritisUSPTOApplication 19073644
- PendingGrowth Factor RestorationUSPTOApplication 17750224
Show all 14 patent records
- Adjustable Gene TherapyMay 28, 2026 · Application 19357344Pending
- Treatment For OsteoarthritisSep 25, 2025 · Application 19073644Pending
- Growth Factor RestorationDec 8, 2022 · Application 17750224Pending
- Optimized Dna Cassettes For Gene TherapyApplication PCTUS2025039707Pending
- A System For Delivering Genetic Material Subcutaneously With Elements Enabling Subsequent Post-treatment Identification, Localization, Quantification, Evaluation, Or Targeting For Up- And/or Down-titrationApplication PCTUS2025035006Pending
- Genetic Elements For Adjustment Of ExpressionApplication PCTUS2024045412Pending
- Adjustable Gene TherapyApplication PCTUS2024024375Pending
- Treatment For OsteoarthritisApplication PCTUS2023073641Pending
- Adjustable Gene TherapyApplication 63459417Pending
- Treatment For OsteoarthritisApplication 63404294Pending
- Non-viral Gene Delivery System CompositionsApplication PCTUS2025053313Pending
- Growth Factor RestorationApplication PCTUS2020061486Pending
- Nanoparticle Formulations For The Delivery Of Dna To Adipose TissueApplication PCTUS2025052563Pending
- Nuclear Translocation Enabling Sequences For Increased Gene Therapy PotencyApplication PCTUS2025043326Pending
Related companies, and why
- Capture Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Helicore BiopharmaSimilar federal contract value in Biotech · null in contracts
- AlltrnaSimilar federal contract value in Biotech · null in contracts
- Immune Response BioPharma, Inc.Similar federal contract value in Biotech · null in contracts
- Cornerstone Genomics Inc.Similar federal contract value in Biotech · null in contracts
- Foghorn TherapeuticsSimilar federal contract value in Biotech · null in contracts
Press
Lifespan Vision Ventures Leads Remedium Bio's Series A FinancingPR Newswire UK
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .